FIELD: chemistry.
SUBSTANCE: invention relates to application of compounds of formula 
I, where R1 represents hydrogen atom, C1-7-alkyl, C1-7-alkoxy, C1-7-alkyl, substituted with halogen atom, C1-7-alkoxy, substituted with halogen atom, halogen atom, cyano, nitro, hydroxy, C(O)O-C1-7-alkyl, S(O)2-C1-7-alkyl, C(O)OCH2-phenyl, OCH2-phenyl, tetrazol-1-yl, phenyl, possibly substituted with halogen atom, or represents phenyloxy, possibly substituted with halogen atom, or represents benzyl, possibly substituted with halogen atom, or represents benzyloxy, possibly substituted with halogen atom; in case, when n>1, R1 substituents can be similar or different; X represents -O-(CH2)2-, -O-CHR"-CH2-, -O-CH2-CHR', -O-CR"2-CH2-, -(CH2)2-CHR'-, -CHR'-(CH2)2-, -CR"2-(CH2)2-, -CH2-CHR'-CH2-, -CH2-CR"2-CH2-, -CHR"-O-CH2-, -CR"2-O-CH2-, -CF2(CH2)2-, -CR"2-CH2-, -SiR"2-(CH2)2-, -S-(CH2)2-, -S(O)2-(CH2)2-, -(CH2)4-, -CH2-O-(CH2)2-, formula 
(a) or 
(b), where m has value 0, 1, 2 or 3; R' represents C1-7-alkyl, C1-7-alkoxy or C1-7-alkyl, substituted with halogen atom; R" represents C1-7-alkyl or C1-7-alkyl, substituted with halogen atom; R2 represents hydrogen atom or C1-7-alkyl; Y represents phenyl, naphthyl, C3-6-cycloalkyl or pyridin-2- or 3-yl, pyrimidin-2-yl or quinolin-6 or 7-yl; n has value 1, 2 or 3; or pharmaceutically acceptable salt of acid attachment in manufacturing medication for treatment anxiety disorders, bipolar disorder, stress-induced disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson disease, neurodegenerative disorders, Alzheimer's disease, epilepsy and migraine. Invention also relates to compounds of formula I, where R1 represents hydrogen atom, C1-7-alkyl, C1-7-alkoxy, C1-7-alkyl, substituted with halogen atom, C1-7-alkoxy, substituted with halogen atom, halogen atom, cyano, nitro, hydroxy, C(O)O-C1-7-alkyl, S(O)2-C1-7-alkyl, C(O)OCH2-phenyl, OCH2phenyl, tetrazol-1-yl, phenyl, possibly substituted with halogen atom, or represents phenyloxy, possibly substituted with halogen atom, or represents benzyl, possibly substituted with halogen atom, or represents benzyloxy, possibly substituted with halogen atom; in case when n>1, R1 substituents can be similar or different; X represents -(CH2)2-CHR', -CHR'-(CH2)2-, -CR"2-(CH2)2-, -CH2-CHR'-CH2-, -CH2-CR"2-CH2-, -CF2(CH2)2-, formula (a), where m has value 0, 1, 2 or 3; R' represents C1-7-alkyl, C1-7-alkoxy or C1-7-alkyl, substituted with halogen atom; R" represents C1-7-alkyl or C1-7-alkyl, substituted with halogen atom; R2 represents hydrogen atom or C1-7-alkyl; Y represents phenyl, naphthyl, C3-6-cycloalkyl or pyridin-2- or 3-yl, pyrimidin-2-yl or chinolin-6 or 7-yl; n has value 1, 2 or 3; or pharmaceutically acceptable salt of acid attachment. Also claimed are methods of obtaining formula (I) compounds.
EFFECT: 4,5-dihydro-oxazol-2-ylamine derivatives for treatment of diseases, associated with biological function of receptors, associated with trace amines.
22 cl, 1 tbl, 176 ex
| Title | Year | Author | Number |
|---|---|---|---|
| OXAZOLINE DERIVATIVES FOR TREATING CNS DISORDERS | 2010 |
|
RU2569887C2 |
| DIHYDROOXAZOLE-2-AMINE DERIVATIVES | 2011 |
|
RU2587512C2 |
| HETEROCYCLIC DERIVATIVES AS RECEPTORS ASSOCIATED WITH TRACER AMINES (TAARS) | 2013 |
|
RU2621050C2 |
| 2-AMINO-5,5-DIFLUORO-5,6-DIHYDRO-4H-OXAZINES AS BACE1 AND(OR) BACE2 INHIBITORS | 2010 |
|
RU2515221C2 |
| 2,5,7-SUBSTITUTED OXAZOLPYRIMIDINE DERIVATIVES | 2011 |
|
RU2557246C2 |
| PIPERAZINO[1,2-A]INDOLE-1-ONES AND [1,4] DIAZEPTINO[1,2-A]INDOLE-1-ONE | 2014 |
|
RU2628126C2 |
| NEW 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISEASES | 2008 |
|
RU2473545C2 |
| AROYLAMINO- AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | 2010 |
|
RU2517701C2 |
| DERIVATIVES OF PYRIDINE AND QUINOLINE, METHOD FOR THEIR PREPARING, PHARMACEUTICAL COMPOSITION, USING COMPOUNDS FOR TREATMENT OF DPP-IV-ASSOCIATED DISEASES | 2003 |
|
RU2285693C2 |
| DERIVATIVES OF DIHYDROBENZO[b][1,4]DIAZEPINE-2-ONE AS I mGluR2 ANTAGONISTS | 2002 |
|
RU2270197C2 |
